A Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986308 in Healthy Participants
Latest Information Update: 28 Apr 2022
At a glance
- Drugs BMS-986308 (Primary) ; Furosemide
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 26 Apr 2022 Status changed from recruiting to completed.
- 15 Sep 2021 Planned number of patients changed from 94 to 46.
- 15 Sep 2021 Planned End Date changed from 26 Mar 2022 to 31 Mar 2022.